Short Communication Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/cardiology.2.034
Beta 3-Adrenergic Receptor (β3-AR) Activation at the End of Sustained Ischemia and/or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy
Ruduwaan Salie1,*, Erna Marais2, Amanda Lochner2
- 1South African Medical Research Council, Biomedical Research and Innovation Platform, Cape Town Western Cape, South Africa
- 2Stellenbosch University, Faculty of Medicine and Health Sciences, Division of Medical Physiology, Centre for Cardio-metabolic Research in Africa (CARMA), Cape Town, Western Cape, South Africa
Corresponding Author
Dr. Ruduwaan Salie, Ruduwaan.salie@mrc.ac.za
Received Date: August 01, 2022
Accepted Date: September 09, 2022
Salie R, Marais E, Lochner A. Beta 3-Adrenergic Receptor (β3-AR) Activation at the End of Sustained Ischemia and / or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy. J Clin Cardiol. 2022;3(2):47-50.
Copyright: © 2022 Salie R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Myocardial ischemia; Reperfusion injury; Cardioprotection; β3-AR modulation
Recommended Articles
Sonoreperfusion Therapy for Microvascular Obstruction: A Review
Coronary artery disease and acute myocardial infarction are a leading cause of morbidity and mortality. Contemporary therapy is percutaneous coronary intervention (PCI), performed by balloon angioplasty and stent placement.
Should we Target Myostatin, PCSK9 or Their Combination in Ischemia or Reperfusion Injury?
Ischemia/reperfusion (I/R) injury is the consequence of a transient interruption of the blood supply for pathologic, traumatic or surgical reasons, followed by flow restoration with rapid hemodynamic changes in the downstream tissues and organs.
Beta 3-Adrenergic Receptor (β3-AR) Activation at the End of Sustained Ischemia and/or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy
The contribution of β3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating β3-AR pharmacology for potential therapeutic applications. These conceptions largely contribute to the discrepancies of the subsequent role of β3-AR activation in the cardiovascular disease process.